Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase 1a/1b, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, immune response, and pharmacokinetics of autogene cevumeran (RO7198457) as a single agent and in combination with atezolizumab (MPDL3280A, an engineered anti-programmed death-ligand 1 [anti-PD-L1] antibody).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Cancer-Specific Inclusion Criteria:
Additional Inclusion Criteria for Participants in Each Indication-Specific Exploration/Expansion Cohort of Phase 1b:
Additional Inclusion Criteria for Participants in the Serial-Biopsy Expansion Cohort of Phase 1b:
Exclusion criteria
All Cohorts (Dose-Escalation in Phase 1a and Dose-Escalation, Backfill, and Expansion in Phase 1b):
Treatment-Specific Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
272 participants in 5 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal